Persistent tumor mutation burden linked with therapeutic response to immunotherapy

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.

Related Keywords

Noushin Niknafs ,Valsamo Anagnostou ,Johns Hopkins ,Emily Henderson ,Bloomberg Kimmel Institute For Cancer Immunotherapy ,Johns Hopkins Kimmel Cancer Center ,Lung Cancer Precision Medicine Center ,Kimmel Institute ,Johns Hopkins Molecular Tumor Board ,Cancer Genome Atlas ,Johns Hopkins Kimmel Cancer ,Immunotherapy ,Biomarker ,Dancer ,Ancer Immunotherapy ,Fell ,Iagnostics ,Enetic ,Enome ,Enomic ,Head And Neck Cancer ,Immune Response ,Immune System ,Lung Cancer ,Medicine ,Melanoma ,Mesothelioma ,Utation ,Neck ,Ncology ,Mh ,Precision Medicine ,Research ,Humor ,